![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HLA-DPA1 |
Gene summary for HLA-DPA1 |
![]() |
Gene information | Species | Human | Gene symbol | HLA-DPA1 | Gene ID | 3113 |
Gene name | major histocompatibility complex, class II, DP alpha 1 | |
Gene Alias | DP(W3) | |
Cytomap | 6p21.32 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | P20036 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3113 | HLA-DPA1 | GSM4909287 | Human | Breast | IDC | 6.52e-27 | 7.47e-01 | 0.2057 |
3113 | HLA-DPA1 | GSM4909290 | Human | Breast | IDC | 1.56e-05 | 2.71e-01 | 0.2096 |
3113 | HLA-DPA1 | GSM4909293 | Human | Breast | IDC | 9.07e-08 | 2.27e-01 | 0.1581 |
3113 | HLA-DPA1 | GSM4909305 | Human | Breast | IDC | 2.63e-02 | 2.19e-01 | 0.0436 |
3113 | HLA-DPA1 | GSM4909317 | Human | Breast | IDC | 8.08e-06 | 2.80e-01 | 0.1355 |
3113 | HLA-DPA1 | M1 | Human | Breast | IDC | 1.37e-17 | 5.64e-01 | 0.1577 |
3113 | HLA-DPA1 | M2 | Human | Breast | IDC | 1.83e-05 | 6.44e-01 | 0.21 |
3113 | HLA-DPA1 | NCCBC11 | Human | Breast | DCIS | 3.90e-09 | 8.54e-01 | 0.1232 |
3113 | HLA-DPA1 | NCCBC14 | Human | Breast | DCIS | 2.42e-07 | 4.77e-01 | 0.2021 |
3113 | HLA-DPA1 | NCCBC3 | Human | Breast | DCIS | 1.57e-73 | 1.47e+00 | 0.1198 |
3113 | HLA-DPA1 | NCCBC5 | Human | Breast | DCIS | 5.80e-28 | 9.67e-01 | 0.2046 |
3113 | HLA-DPA1 | P2 | Human | Breast | IDC | 4.77e-26 | 9.60e-01 | 0.21 |
3113 | HLA-DPA1 | DCIS2 | Human | Breast | DCIS | 1.03e-02 | 4.32e-02 | 0.0085 |
3113 | HLA-DPA1 | CA_HPV_1 | Human | Cervix | CC | 5.76e-10 | 6.60e-01 | 0.0264 |
3113 | HLA-DPA1 | CA_HPV_3 | Human | Cervix | CC | 4.76e-02 | -4.65e-01 | 0.0414 |
3113 | HLA-DPA1 | N_HPV_1 | Human | Cervix | N_HPV | 3.00e-05 | 2.45e-01 | 0.0079 |
3113 | HLA-DPA1 | CCI_1 | Human | Cervix | CC | 6.16e-10 | -1.04e+00 | 0.528 |
3113 | HLA-DPA1 | CCI_3 | Human | Cervix | CC | 9.65e-08 | -9.64e-01 | 0.516 |
3113 | HLA-DPA1 | CCII_1 | Human | Cervix | CC | 1.70e-18 | -1.04e+00 | 0.3249 |
3113 | HLA-DPA1 | Tumor | Human | Cervix | CC | 1.26e-17 | -5.58e-01 | 0.1241 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00343413 | Liver | Cirrhotic | response to interferon-gamma | 60/4634 | 141/18723 | 2.57e-06 | 4.63e-05 | 60 |
GO:0071346 | Liver | Cirrhotic | cellular response to interferon-gamma | 49/4634 | 118/18723 | 4.43e-05 | 5.22e-04 | 49 |
GO:00024787 | Liver | Cirrhotic | antigen processing and presentation of exogenous peptide antigen | 21/4634 | 38/18723 | 5.49e-05 | 6.31e-04 | 21 |
GO:00198827 | Liver | Cirrhotic | antigen processing and presentation | 44/4634 | 106/18723 | 1.07e-04 | 1.10e-03 | 44 |
GO:00480027 | Liver | Cirrhotic | antigen processing and presentation of peptide antigen | 29/4634 | 62/18723 | 1.34e-04 | 1.31e-03 | 29 |
GO:00457857 | Liver | Cirrhotic | positive regulation of cell adhesion | 141/4634 | 437/18723 | 2.05e-04 | 1.89e-03 | 141 |
GO:00198847 | Liver | Cirrhotic | antigen processing and presentation of exogenous antigen | 23/4634 | 47/18723 | 2.84e-04 | 2.51e-03 | 23 |
GO:00023965 | Liver | Cirrhotic | MHC protein complex assembly | 12/4634 | 19/18723 | 4.35e-04 | 3.55e-03 | 12 |
GO:00198866 | Liver | Cirrhotic | antigen processing and presentation of exogenous peptide antigen via MHC class II | 16/4634 | 30/18723 | 7.20e-04 | 5.36e-03 | 16 |
GO:00025015 | Liver | Cirrhotic | peptide antigen assembly with MHC protein complex | 11/4634 | 18/18723 | 1.13e-03 | 7.73e-03 | 11 |
GO:00025045 | Liver | Cirrhotic | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 17/4634 | 36/18723 | 2.82e-03 | 1.63e-02 | 17 |
GO:00024955 | Liver | Cirrhotic | antigen processing and presentation of peptide antigen via MHC class II | 16/4634 | 34/18723 | 3.88e-03 | 2.10e-02 | 16 |
GO:00023995 | Liver | Cirrhotic | MHC class II protein complex assembly | 9/4634 | 16/18723 | 6.94e-03 | 3.38e-02 | 9 |
GO:00025035 | Liver | Cirrhotic | peptide antigen assembly with MHC class II protein complex | 9/4634 | 16/18723 | 6.94e-03 | 3.38e-02 | 9 |
GO:001988212 | Liver | HCC | antigen processing and presentation | 65/7958 | 106/18723 | 7.06e-05 | 6.37e-04 | 65 |
GO:00343411 | Liver | HCC | response to interferon-gamma | 82/7958 | 141/18723 | 1.25e-04 | 1.03e-03 | 82 |
GO:00713461 | Liver | HCC | cellular response to interferon-gamma | 70/7958 | 118/18723 | 1.66e-04 | 1.32e-03 | 70 |
GO:000247811 | Liver | HCC | antigen processing and presentation of exogenous peptide antigen | 27/7958 | 38/18723 | 3.47e-04 | 2.42e-03 | 27 |
GO:004800212 | Liver | HCC | antigen processing and presentation of peptide antigen | 40/7958 | 62/18723 | 3.84e-04 | 2.62e-03 | 40 |
GO:001988611 | Liver | HCC | antigen processing and presentation of exogenous peptide antigen via MHC class II | 22/7958 | 30/18723 | 6.14e-04 | 3.82e-03 | 22 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0461223 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
hsa0414522 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
hsa0541623 | Breast | IDC | Viral myocarditis | 18/867 | 60/8465 | 1.85e-05 | 2.01e-04 | 1.50e-04 | 18 |
hsa0516624 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0532321 | Breast | IDC | Rheumatoid arthritis | 21/867 | 93/8465 | 3.69e-04 | 3.15e-03 | 2.36e-03 | 21 |
hsa0494014 | Breast | IDC | Type I diabetes mellitus | 12/867 | 43/8465 | 9.40e-04 | 7.28e-03 | 5.44e-03 | 12 |
hsa0533012 | Breast | IDC | Allograft rejection | 11/867 | 38/8465 | 1.09e-03 | 8.26e-03 | 6.18e-03 | 11 |
hsa0533210 | Breast | IDC | Graft-versus-host disease | 11/867 | 42/8465 | 2.66e-03 | 1.80e-02 | 1.35e-02 | 11 |
hsa0514012 | Breast | IDC | Leishmaniasis | 16/867 | 77/8465 | 4.35e-03 | 2.57e-02 | 1.92e-02 | 16 |
hsa0532010 | Breast | IDC | Autoimmune thyroid disease | 12/867 | 53/8465 | 6.29e-03 | 3.30e-02 | 2.47e-02 | 12 |
hsa0516932 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0461233 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
hsa0414532 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
hsa0541633 | Breast | IDC | Viral myocarditis | 18/867 | 60/8465 | 1.85e-05 | 2.01e-04 | 1.50e-04 | 18 |
hsa0516634 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0532331 | Breast | IDC | Rheumatoid arthritis | 21/867 | 93/8465 | 3.69e-04 | 3.15e-03 | 2.36e-03 | 21 |
hsa0494015 | Breast | IDC | Type I diabetes mellitus | 12/867 | 43/8465 | 9.40e-04 | 7.28e-03 | 5.44e-03 | 12 |
hsa0533013 | Breast | IDC | Allograft rejection | 11/867 | 38/8465 | 1.09e-03 | 8.26e-03 | 6.18e-03 | 11 |
hsa0533211 | Breast | IDC | Graft-versus-host disease | 11/867 | 42/8465 | 2.66e-03 | 1.80e-02 | 1.35e-02 | 11 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Breast | DCIS |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Breast | Healthy |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Breast | IDC |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Cervix | ADJ |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Cervix | CC |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Cervix | Healthy |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Cervix | Precancer |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | CRC | AD |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | CRC | ADJ |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | CRC | MSI-H |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | CRC | MSS |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | CRC | SER |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Endometrium | ADJ |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Endometrium | AEH |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Endometrium | EEC |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | Endometrium | Healthy |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | HNSCC | ADJ |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | HNSCC | Healthy |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | HNSCC | OSCC |
HLA-DPA1 | CD4 | HLA-DPA1_CD4 | MHC-II | HNSCC | Precancer |
Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HLA-DPA1 | SNV | Missense_Mutation | c.397C>T | p.Pro133Ser | p.P133S | P20036 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
HLA-DPA1 | SNV | Missense_Mutation | novel | c.325N>G | p.Asn109Asp | p.N109D | P20036 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-DPA1 | SNV | Missense_Mutation | rs770307009 | c.746N>A | p.Arg249His | p.R249H | P20036 | protein_coding | tolerated(0.21) | benign(0.005) | TCGA-CM-4747-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | fluorouracil | SD |
HLA-DPA1 | SNV | Missense_Mutation | rs371532700 | c.137C>T | p.Thr46Met | p.T46M | P20036 | protein_coding | deleterious(0.04) | possibly_damaging(0.895) | TCGA-G4-6295-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HLA-DPA1 | SNV | Missense_Mutation | c.100N>A | p.Ala34Thr | p.A34T | P20036 | protein_coding | deleterious(0.03) | benign(0.106) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
HLA-DPA1 | SNV | Missense_Mutation | c.484G>T | p.Gly162Cys | p.G162C | P20036 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
HLA-DPA1 | SNV | Missense_Mutation | rs751649425 | c.724N>A | p.Val242Ile | p.V242I | P20036 | protein_coding | tolerated(1) | benign(0) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-DPA1 | SNV | Missense_Mutation | novel | c.446N>G | p.Asn149Ser | p.N149S | P20036 | protein_coding | tolerated(0.18) | benign(0.033) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-DPA1 | SNV | Missense_Mutation | rs761093053 | c.5N>A | p.Arg2His | p.R2H | P20036 | protein_coding | tolerated_low_confidence(0.56) | benign(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-DPA1 | SNV | Missense_Mutation | novel | c.718G>A | p.Gly240Ser | p.G240S | P20036 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3113 | HLA-DPA1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, CELL SURFACE | peginterferon alfa-2b | 26387494 |
Page: 1 |